Scott Sellinger, MD, FACS, explains the biologic significance of PTEN loss in metastatic prostate cancer, why it is associated with aggressive disease and poor outcomes, and how the approval of capivasertib has transformed PTEN from a prognostic biomarker into a predictive biomarker with a targeted treatment option.